GSK withdraws applications for Avodart | InPharm
Links shared publicly online about this topic.
- 413total visits
GSK withdraws applications for Avodart | InPharm
InPharm.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, jobs, events, and service company listings.
View full resource at inpharm.com
Tags: Benign Prostatic Hypertrophy Medication, Pharma, Avodart, GlaxoSmithKline, News, Event
Most Recently Shared on March 25, 2011 at 4:58 pm By:
GSK withdraws applications for Avodart http://goo.gl/fb/avTCr
GlaxoSmithKline drops Avodart for prostate cancer risk reduction - Pharmaceutical and Biotechnology News - Pharma Letter
thepharmaletter.com — “UK pharma giant GlaxoSmithKline (LSE: GSK) says that it will no longer pursue global approval for the use of Avodart (dutasteride) to reduce the risk of prostate cancer. The company will withdraw applications from regulatory review where procedures are on” View full resource at thepharmaletter.com
Most Recently Shared on March 24, 2011 at 5:35 pm By:
GlaxoSmithKline drops Avodart for prostate cancer risk reduction http://bit.ly/gRCa25
Advertisement
